

***qnr* Prevalence in Extended Spectrum Beta-lactamases (ESBLs) and Non-ESBLs Producing *Escherichia coli* Isolated from Urinary Tract Infections in Central of Iran**

¹Iraj Pakzad, *¹Sobhhan Ghafourian, ¹Morovat Taherikalani, ¹Norkhoda sadeghifard, ²Hamid Abtahi, ³Mohammad Rahbar, ⁴Neda Mansory Jamshidi

Abstract

Objective(s)

Extensive use of quinolones has been associated with raising level of resistance. In the current, we focused on assessing the prevalence of *Escherichia coli* resistance to quinolones and frequency of *qnrA*, *qnrB* and *qnrS* in non ESBLs (extended spectrum beta-lactamases) and ESBLs producing *E. coli* with *blaSHV* and *blaTEM*.

Materials and Methods

One hundred and fifty *E. coli* isolates were identified during Mar. 2007 to Apr. 2008 in Milad (Tehran) hospital. They were tested for ESBLs production as well as quinolone resistance. PCR was performed for detection of *blaSHV* and *blaTEM* as well as *qnrA*, B and S.

Results

Of 150 isolates, forty-two (28%) ESBLs producing and one hundred and eight (72%) non-ESBLs producing *E. coli* were identified. 64.2% (n= 24) of *E. coli* producing ESBLs and 4.62% (n= 5) of non-ESBLs *E. coli* were resistance to ciprofloxacin. 95.2% (n= 40) and 26.1% (n= 11) of the isolates harbored *blaTEM* and *blaSHV*, respectively. 23.8% (n= 10) had both genes. 37.5% (n= 9) and 20.8% (n= 4) of ESBLs producing *E. coli* were positive for *qnrA* and *qnrB* respectively. *qnrS* was not identified in any isolate.

Conclusion

Our study showed high frequency of ESBLs producing *E. coli* as well as quinolone resistance genes (*qnrA*, *qnrB*) in Milad hospital.

Keywords: Ciprofloxacin, Iran, Resistance

1- Department Microbiology, Faculty of Medicine and Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

*Corresponding author: Tel: +98-841-3342272; Fax: +98-841-2227134; email: sobhanghafurian@yahoo.com

2- Department Microbiology, Faculty of Medicine and Molecular Medicine Research Center, Arak University of Medical Sciences, Arak, Iran

3- Department Microbiology, Iranian Reference Health Laboratory, Tehran, Iran

4- Department Microbiology, Karaj Islamic Azad University, Karaj/Iran

Introduction

Low-level quinolone resistance has been associated with DNA acquired from transferable plasmids. Several studies showed a worldwide dissemination of qnr determinants among bacterial isolates (1, 2). Quinolones are broad-spectrum antibacterial agents, commonly used both in human and veterinary medicine. Their extensive use has been associated with raising level of quinolone resistance (3). The two main mechanisms of quinolone resistance are chromosomally encoded, being either modification of the quinolone targets with changes of DNA gyrase (*gyrA*) and/or topoisomerase IV (*parC*) genes, or decreased intracellular concentration due to impermeability of the membrane or overexpression of efflux pump systems (4-6). The geographical distribution of *qnrA* genes is known to be wide (6), but those of the newer *qnr* types (*qnrB* (4) and *qnrS* (3)) have not been studied. Prior studies have not evaluated temporal changes in prevalence either.

qnrA confers resistance to quinolones such as nalidixic acid and increases MICs of fluoroquinolones up to 32-fold in *Escherichia coli* (5, 6). In addition, it favors selection of associated chromosome-encoded quinolone resistance determinants that confer additional resistance to fluoroquinolones. The *qnrA*-like determinants have been reported worldwide from many enterobacterial species and six variants have been identified so far (*qnrA1* to *qnrA6*). Other plasmid-mediated quinolone resistance determinants, *qnrB* (*qnrB1* to *qnrB6*) and *qnrS* (*qnrS1* and *qnrS2*) have been also identified in enterobacterial species, sharing 41% and 60% amino acid identity with *qnrA*, respectively (8, 9).

Beta-lactam antimicrobial agents are the most common treatment for bacterial infections. Rates of bacterial resistance to antimicrobial agents are increasing worldwide. Production of beta-lactamases is the most common mechanism of bacterial resistance (10). These enzymes are numerous, and they mutate continuously in response to the heavy pressure of antibiotic use, leading to the development of extended spectrum beta-

lactamases (ESBLs) (11, 12). The ESBL producing bacteria are typically associated with multidrug resistance, because genes with other mechanisms of resistance often reside on the same plasmid as the ESBL gene. Thus, some ESBL producing strains also show resistance to quinolones, aminoglycosides, and trimethoprim-sulfamethoxazole (12).

In the current study we focused on assessing the prevalence of *E. coli* resistance to quinolones and frequency of *qnrA*, *qnrB* and *qnrS* in ESBLs and non ESBLs producing *E. coli* with *blaSHV* and *blaTEM* in Milad Hospital (Tehran).

Materials and Methods

Bacterial isolates

One hundred and fifty *E. coli* isolates were identified during Mar. 2007 to Apr. 2008 from urinary tract infections in Milad (Tehran) hospital. They were tested for ESBLs production as well as quinolone resistance.

Detection of ESBLs producing *E. coli*

The methods for the laboratory detection of ESBLs were based on recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) and the Canadian External Quality Assessment Advisory Group for Antibiotic Resistance. However, we made some modifications in order to address the differences in the operations of laboratories in our settings. All the clinically significant isolates of *E. coli*, were tested against beta lactam drugs using a disc diffusion method (as advocated by the revised NCCLS interpretive criteria). Any decrease in the zone sizes for the 3rd generation cephalosporins was used as a criterion for ESBLs production (13).

ESBL screening methods

Standard disc diffusion method

In vitro sensitivity testing was performed using established NCCLS procedure with ceftazidim (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), aztreonam (30 µg) and cefpodoxime (30 µg). The zone diameters were read using the revised NCCLS. Any zone diameter within the "grey zone" was considered a probable ESBL producing strain requiring phenotypic confirmatory testing (14, 15).

Phenotypic confirmatory method

Ceftazidime (30 µg) versus ceftazidime/clavulanic (30/10 µg), cefotaxime (30 µg) versus (cefotaxime /clavulanic acid (30/10 µg) and cefpodoxime versus (cefpodoxime /clavulanic acid) were placed into a Muller-Hinton agar plate lined with the test organism and incubated as described above. Regardless of the zone diameters, a > 5 mm increase in a zone diameter for an antimicrobial agent tested in combination with clavulanic acid versus its zone size when tested alone, indicated a probable ESBL production (16).

E. coli ATCC 25922 was used as a negative control and *Klebsiella pneumoniae* ATCC 700603 as an ESBL positive control. *K. pneumoniae* ATCC 700603 diameter ranges were as follows: cefpodoxime (10 µg) 6-9 mm, ceftazidime (30 µg) 10-18 mm, cefotaxime (30 µg) 17-25 mm, ceftriaxone (30 µg) 16-24 mm, aztreonam (30 µg) 9-17 mm.

Quinolone resistance detection

For detection of quinolone resistance, disk diffusion was performed as CLSI recommended by using ciprofloxacin (5 µg) disk. *E. coli* isolates which were resistant to ciprofoloxacin were suspected to harbor qnr genes (16).

DNA extraction and PCR

E. coli was cultured in LB broth at 37 °C

overnight, and then DNA was extracted using the DNA extraction KIT (fermentase, Spain).

PCR detection of blaTEM and blaSHV and qnr genes

Specific primers in Table 1 were used. For blaTEM and blaSHV PCR conditions were 94 °C for 45 sec, 44 °C for 45 sec for blaTEM and 56 °C for blaSHV, and 72 °C for 60 sec, with a cycle number of 32. The PCR conditions for qnr genes were 94 °C for 45 sec, 53 °C for 45 sec, and 72 °C for 60 sec, with a cycle number of 32 (7).

Results

Of one hundred and fifty isolates from urinary tract infections during Mar. 2007 to Apr. 2008 in Milad Hospital, forty-two (28%) *E. coli*, produced ESBLs and one hundred and eight (72%) were non-ESBLs *E. coli* isolates:

Screening stage

Of one hundred and fifty isolates from urinary tract infections, 69.3% (n= 104), 39.3% (n= 59), 28% (n= 42), 50.6% (n= 76) and 28% (n= 42) were resistant to ceftazidim, cefotaxime, cefpodoxime, ceftetriaxone and aztreonam, respectively (Table 2). As definition, ESBLs are defined as extended-spectrum because they are able to hydrolyze a broader spectrum of beta-lactam antibiotics than the simple parent beta- lactamases from which they are derived.

Table 1. Primers used for PCR detection of blaTEM, blaSHV and qnr genes.

	Primers	Size of amplicins	References
BlaSHV	F:5-AAGATCCACTATCGCCAGCAG-3 R: 5-ATTCAGTTCGGTTTCCCAGCGG-3	235 bp	(13)
BlaTEM	F: 5-GAGTATCAACATTTCCGTGTC3 R: 5-TAATCAGTGAGGCACCTTCTC-3	889 bp	(13)
qnrA	F:5-ATTTCTCACGCCAGGATTTG R: 5-GATCGGCAAAGGTTAGGTCA-3	516 bp	(7)
qnrB	F: 5-GATCGTGAAAGCCAGAAAGG-3 R: 5-ACGATGCCTGGTAGTTGTCC-3	469 bp	(7)
qnrS	F:5-ACGACATTCGTCAACT GCAA-3 R: 5-TAAATTGGCACCCCTGTAGGC-3	417 bp	(7)

Table 2. Frequency of resistance of *E. coli* isolated from UTI to 3rd generation cephalosporins and monobactam.

	Ceftazidim resistance	Cefotaxime resistance	Cefpodoxime resistance	Ceftetriaxone resistance	Azteronam resistance
<i>E. coli</i> isolated from UTI	104 (69.3%)	59 (39.3%)	42 (28%)	76 (50.6%)	42 (28%)

Such ESBLs have also the ability to inactivate beta-lactam antibiotics containing an oxyimino-group such as oxyimino-cephalosporins (e.g.; ceftazidime, ceftriaxone, cefotaxime) as well as oxyimino-monobactam (17). Furthermore, they are not active against cephamycins and carbapenems. Generally, they are inhibited by beta-lactamase-inhibitors such as clavulanate and tazobactam. Any resistance to one or more of 3rd generation of cephalosporins and azteroname is suspicious for ESBLs production. In our study, forty two *E. coli* isolates were suspected to produce ESBLs.

Confirming stage

Confirming stage was done for *E. coli* isolates suspected to produce ESBLs by ceftazidim /clavulanic acid, cefotaxime/clavulanic acid, and cefpodoxime/clavulanic acid. All the *E. coli* isolates suspected to produce ESBLs (n= 42) were confirmed by cefpodoxime/clavulanic acid. 90.4% (n= 38) and 57.1% (n= 24) were confirmed by ceftazidime/clavulanic acid, cefotaxime/clavulanic acid, respectively.

Ciprofloxacin resistance

All the isolates were tested for ciprofloxacin resistance. 64.2% (n= 24) of ESBLs producing *E. coli* and 4.62% (n= 5) of non-ESBLs producing *E. coli* isolates were resistance to ciprofloxacin using disk diffusion method. Thus, 19.3% (n= 29) of all isolates were resistance to ciprofloxacin.




Figure 1. Frequency of blaSHV, blaTEM and blaSHV-blaTEM in ESBLs producing *E. coli* isolates, 95.2% (n= 40) and 26.1% (n= 11) harbored blaTEM, blaSHV, and 21.4% (n= 9) had both genes.




Figure 2. Frequency of qnr A, qnrB and qnrS in ESBLs and nono-ESBLs producing *E. coli* isolates: 37.5% (n= 9), 20.8% (n= 4) and 0% were positive for qnrA, qnrB and qnrS, respectively.




Figure 3. Electrophoresis of PCR product on 1% agarose gel, M (Marker 50 bp), qnrB= 469 bp (lane 1, 2, 3, 4, 5), qnrA =516 bp (lane 6, 7, 8, 9, 10).

PCR for detection of blaTEM and blaSHV

Forty-two ESBLs producing *E. coli* obtained in phenotypic stage were tested for detection of blaTEM and blaSHV. Our results showed, 95.2% (n= 40) and 26.1% (n= 11) blaTEM and blaSHV harboring isolates, respectively. 21.4% (n= 9) had both genes (Figure 1).

PCR for qnrA, qnrB and qnrS

OF Twenty-four *E. coli* producing ESBLs and resistant to ciprofloxacin, all harbored blaTEM and amongst them two isolates possessed blaSHV in addition to blaTEM. 37.5% (n= 9) and 20.8% (n= 4) *E. coli* producing ESBLs (with blaTEM) were positive for qnrA and qnrB, respectively (Figure 3). No qnrS was identified in our study (Figure 3). *E. coli* with both qnrA

and *qnrB* were found in *E. coli* producing ESBLs with both *bla*TEM and *bla*SHV genes. Of five *E. coli* isolates that were non-ESBLs producing, only one isolate harbored *qnrA* (Figure 2).

Discussion

In our study the highest antibiotic resistance occurred to ceftazidim and the lowest was to cefpodoxime and aztreonam. Interestingly, all *E. coli* suspected to produce ESBLs were confirmed by cefpodoxime/clavulanic acid. Resistance to ciprofloxacin was observed in ESBLs producing *E. coli* more than non-ESBLs producing *E. coli* isolates.

Frequency of *bla*TEM was higher than *bla*SHV. *qnrA* was dominant *qnr* followed by *qnrB*. *E. coli* isolates with both *qnrA* and *qnrB* were found in *E. coli* isolates with both *bla*TEM and *bla*SHV while *qnrA* was also found in non-ESBLs producing *E. coli* isolates. Several reports have detected a positive correlation between *qnrA* and the ESBLs production *bla*TEM and *bla*SHV (1, 18, 19). In Chinese pediatric patients clinical isolates of ESBL or AmpC-producing *E. coli* revealed that *qnr*, *aac*(6')-Ib-cr, and ESBL-encoding genes were transferred together (18). *qnrA*-like determinants in ciprofloxacin-resistant *E. coli* isolates collected from 2000 to 2002 were estimated to be 7.7% in Shanghai, China (19). In Germany, *qnrA*-positive *Enterobacter* spp. and *Citrobacter freundii* isolates were detected in four patients in two intensive care units among 703 cephalosporin-resistant or fluoroquinolone-resistant *Enterobacteriaceae* which were tested from 34 German intensive care units from 2000 to 2003 (20). In Korea, *qnrB4* was the most frequent type in both *E. coli* and *K. pneumoniae* isolated from a tertiary care hospital (12). *qnrB* was mainly carried by *E. coli* and *qnrS* by *K. pneumoniae* in healthy children in Peru and Bolivia (21). In Japan close association of *qnr* with *aac*(6')-Ib and *aac*(6')-IIc in clinical isolates of *E. coli* and *K. oxytoca* producing ESBL or MBL was noticed. In clinical isolates of *E. coli* only *qnrS* was identified from Japan (22). *qnrA*

determinants were found in up to 48% of VEB-1-positive enterobacterial isolates from Bangkok, Thailand (23), *qnrB* determinants were associated with the ESBL SHV-12 in several isolates and 62% of ESBLs production of *E. coli* were resistance to ciprofloxacin (23). Our results also showed high resistance to ciprofloxacin which was concordant with the above-mentioned reports. Our study also showed that some of *E. coli* isolates (ESBLs and non-ESBLs producing) didn't have *qnr* genes but were resistant to ciprofloxacin. This indicated other resistance mechanisms such as changes of DNA gyrase (*gyrA*) and/or topoisomerase IV (*parC*) genes, or decreased intracellular concentration due to impermeability of the membrane or overexpression of efflux pump systems (4-6). In this study, high frequency of quinolone resistance genes (*qnrA*, *qnrB*) may be due to fact that all isolates were originated from one hospital. In addition, environmental conditions and the antibiotic burden may affect the frequency of quinolone resistance.

The clinical relevance of the multidrug resistance among ESBL-producing *E. coli* isolates is of great concern due to the severely limited therapeutic options and increased risk of treatment failure in patients infected with such strains (24).

Since plasmids frequently carry both the ESBL and aminoglycoside resistance genes and many *Enterobacteriaceae* species have also chromosomal resistance to quinolones, the ESBL-producing *Enterobacteriaceae* are commonly multidrug resistant (25). Association of antibiotic resistance genes may explain in part the frequent association between fluoroquinolone and expanded spectrum cephalosporin resistance in *E. coli*. In addition, it raises the issue of the nature of antibiotic molecules that may select this co-resistance. We do not know if there is a special link between the two emerging mechanisms of resistance in *E. coli* plasmid-mediated quinolone resistance and ESBL in community-acquired pathogens. This was first report of *qnrA*, *B* in *E. coli* producing ESBLs and undetectable *qnrS* in Iran.

Conclusion

Our study showed that frequency of blaTEM was higher than blaSHV in ESBLs producing *E. coli* isolates, and also quinolone resistance genes qnrA was dominant qnr followed by qnrB.

Acknowledgment

The authors would like to thank Deputy of Research and Technology of Ilam University of Medical Sciences, Iran, for financial and equipments support.

References

- Cheung TK, Chu YW, Chu MY, Ma CH, Yung RW, Kam KM. Plasmid-mediated resistance to ciprofloxacin and cefotaxime in clinical isolates of *Salmonella enterica* serotype Enteritidis in Hong Kong. *J Antimicrob Chemother* 2005; 56:586-589.
- Cerquetti M, Garcia-Fernandez A, Giufrè M, Fortini D, Accogli M, Graziani C, *et al.* First report of plasmid-mediated quinolone resistance determinant *qnrS1* in an *Escherichia coli* strain of animal origin in Italy. *Antimicrob Agents Chemother* 2009; 53:3112-3114.
- Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect Dis* 2006; 6:629-640.
- Oktem IM, Gulay Z, Bicmen M, Gur D. qnrA prevalence in extended-spectrum beta-lactamase-positive Enterobacteriaceae isolates from Turkey. *Jpn J Infect Dis* 2008 ;61:13-17.
- Allou N, Cambau E, Massias L, Chau F, Fantin B. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of *Escherichia coli* urinary tract infection. *Antimicrob Agents Chemother* 2009; 53:4292-4297.
- Poirel L, Pitout J, Calvo L, Rodriguez-Martinez JM, Church D, Nordmann P. In vivo selection of fluoroquinolone-resistant *Escherichia coli* isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. *Antimicrob Agents Chemother* 2006; 50:1525-1527.
- Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. *Antimicrob Agents Chemother* 2006; 50:2872-2874.
- Shin SY, Kwon KC, Park JW, Song JH, Ko YH, Sung JY, *et al.* Characteristics of aac(6)-Ib-cr gene in extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from Chungnam area. *Korean J Lab Med* 2009; 29:541-550.
- Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. *J Antimicrob Chemother* 2005; 56:463-469.
- Dbaiibo GS. Old and new targets of antibacterial therapy. *J Med Liban* 2000; 48:177-181.
- Park Y, Kang HK, Bae IK, Kim J, Kim JS, Uh Y, *et al.* Prevalence of the extended-spectrum beta-lactamase and qnr genes in clinical isolates of *Escherichia coli*. *Korean J Lab Med* 2009; 29:218-223.
- Kim MH, Lee HJ, Park KS, Suh JT. Molecular characteristics of extended spectrum beta-lactamases in *Escherichia coli* and *Klebsiella pneumoniae* and the prevalence of qnr in Extended spectrum beta-lactamase isolates in a tertiary care hospital in Korea. *Yonsei Med J* 2010; 51:768-774.
- Shahcheraghi F, Moezi H, Feizabadi MM. Distribution of TEM and SHV beta-lactamase genes among *Klebsiella pneumoniae* strains isolated from patients in Tehran. *Med Sci Monit* 2007; 13:BR247-250.
- Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, Oliver A, *et al.* Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for *Escherichia coli* with isolates collected during Project ICARE. *J Clin Microbiol* 2003; 41:3142-3146.
- Cormican MG, Marshall SA, Jones RN. Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen. *J Clin Microbiol* 1996; 34:1880-1884.
- Song S, Lee EY, Koh EM, Ha HS, Jeong HJ, Bae IK, *et al.* Antibiotic resistance mechanisms of *Escherichia coli* Isolates from urinary specimens. *Korean J Lab Med* 2009; 29:17-24.
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev* 2005; 18:657-686.
- Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Fishman NO, Bilker WB, *et al.* Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella species*. *Clin Infect Dis* 2005; 40:1317-1324.
- Paterson DL, Bonomo RA. Resistance in gram-negative bacteria: Enterobacteriaceae. *Am J Infect Control* 2006; 34 :S20-28; discussion S64-73.
- Han C, Yang Y, Wang M, Wang A, Lu Q, Xu X, *et al.* The prevalence of plasmid-mediated quinolone resistance determinants among clinical isolates of ESBL or AmpC-producing *Escherichia coli* from Chinese pediatric patients. *J Microbiol Immunol* 2010; 54:123-128.
- Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. Plasmid-mediated quinolone resistance in clinical isolates of *Escherichia coli* from Shanghai, China. *Antimicrob Agents Chemother* 2003; 47:2242-2248.

22. Jonas D, Biehler K, Hartung D, Spitzmüller B, Daschner FD. Plasmid-mediated quinolone resistance in isolates obtained in German intensive care units. *Antimicrob Agents Chemother* 2005; 49:773-775.
23. Pallecchi L, Riccobono E, Mantella A, Bartalesi F, Sennati S, Gamboa H, *et al*. High prevalence of qnr genes in commensal enterobacteria from healthy children in Peru and Bolivia. *Antimicrob Agents Chemother* 2009; 53: 2632-2635(2009).
24. Ode T, Saito R, Kumita W, Sato K, Okugawa S, Moriya K, *et al*. Analysis of plasmid-mediated multidrug resistance in *Escherichia coli* and *Klebsiella oxytoca* isolates from clinical specimens in Japan. *Int J Antimicrob Agents* 2009; 34:347-350.
25. Poirel, Van De Loo M, Mammeri H, Nordmann P. Association of plasmid-mediated quinolone resistance with extended-spectrum beta-lactamase VEB-1. *Antimicrob Agents Chemother* 2005; 49:3091-3094.